Status:
COMPLETED
Maintenance Study on the Long Term Safety of XL999
Lead Sponsor:
Symphony Evolution, Inc.
Conditions:
Advanced Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999. The secondary objectives of this study are as follows...
Eligibility Criteria
Inclusion
- The subject is currently enrolled in Protocols XL999-001 or XL999-204
- The subject has received XL999 for at least one year prior to enrollment
- Per the respective parent XL999 protocol, the subject is eligible to continue to receive XL999 in the absence of progressive disease (PD) or unacceptable drug-related toxicity
Exclusion
- Progressive disease
- Any development(s) that would meet the exclusion criteria from the subject's respective XL999 protocol (XL999-001 or XL999-204)
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00955084
Start Date
August 1 2008
End Date
May 1 2010
Last Update
September 24 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology Oncology Associates of Rockland Union State Bank Cancer Center
Nyack, New York, United States, 10960
2
University of Texas Cancer Center
San Antonio, Texas, United States, 78229